BRAF and cancer: The development of paradox breaker compounds is expected to provide significant impact to anticancer therapy, as they allow to efficiently modulate the activity of mutant B-RafV600E, while circumventing protein dimerization.41 However, such compounds might also result in limited efficacy towards cancers with mutated Ras, according to literature data.41 Despite the advantages that can be observed in latest-generation ATP-competitive inhibitors of this kinase, several evidences encouraged a number of research groups to develop B-Raf modulators acting through innovative mechanisms.